Meeting
2023 ASCO Genitourinary Cancers Symposium
Refining the serum miR-371a-3p test for viable germ cell tumor detection: Identification and definition of an indeterminate range.
Authors
Aditya Bagrodia
University of California San Diego Health, La Jolla, CA
Aditya Bagrodia , John T. Lafin , Cinzia Scarpini , Bendu Konneh , Thomas Gerald , Michelle Nuno , Jin Piao , Anna Savelyeva , Liwei Jia , Sarah Murray , Yun Cheng , Vitaly Margulis , Solomon L. Woldu , Nicholas Coleman , James F. Amatruda , Lindsay Lindsay Frazier , Matthew Murray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 425)
DOI
10.1200/JCO.2023.41.6_suppl.425
Abstract #
425
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pre-orchiectomy serum miRNA-371a-3p and 372-3p levels in men with clinically localized testicular masses.
First Author: Fady Baky
Poster
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
First Author: Nirmish Singla
Poster
2018 ASCO Annual Meeting
Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.
First Author: Lucia Nappi
Poster
2018 Genitourinary Cancers Symposium
Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.
First Author: Lucia Nappi